Tecentriq may be used with the medicines cobimetinib and vemurafenib in patients with melanoma when their skin cancer: has spread to other parts of the body or cannot be removed by surgery, and; ...

Tecentriq can cause serious side effects, including: Lung problems (pneumonitis)–signs and symptoms of pneumonitis may include new or worsening cough, shortness of breath, and chest pain ...

Merck’s MRK primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust ...

Basel, 09 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) as an adjuvant treatment, following complete resection ...

Genentech, a member of the Roche Group, today announced that the Phase III IMscin001 study evaluating a subcutaneous formulation of Tecentriq ® met its co-primary endpoints. "By reducing the ...

Tecentriq is available as a liquid solution that’s given as an IV infusion (an injection into your vein over a period of time). You’ll receive infusions at your doctor’s office or a clinic.

About Tecentriq ® (atezolizumab) Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating ...

Zepzelca plus Tecentriq improved PFS and OS in ES-SCLC patients compared to Tecentriq alone, with a median PFS of 5.4 months versus 2.1 months. The combination therapy showed a median OS of 13.2 ...

Tecentriq is currently approved as a treatment for patients with metastatic NSCLC following progression on a platinum-containing regimen, and an FDA-approved targeted therapy for those patients ...

But Tecentriq has two other key trials in early-stage liver cancer and non-small cell lung cancer that could read out this year, and both are in relatively familiar territory for the treatment.

Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) plus Cotellic® (cobimetinib) and ...

Bernstein’s own estimates put Tecentriq at $4.9 billion by 2021. It is forecasting Opdivo at $8.1 billion and Keytruda at $6.5 billion, with AstraZeneca’s yet-to-be-approved PD-L1 checkpoint ...